

Jessie Xie

Biography


As a seasoned member of our Life Science and Health Care Group, Jessie has developed her practice to cover all types of regulatory work in the medical device, pharmaceutical, healthcare, food and cosmetic industry sectors in China. She believes that the goal is not always to answer the question, but to help you achieve a competitive advantage and minimize regulatory risk.

Jessie is familiar with product approval, clinical trials, adverse event report, product recalls, labeling, advertising requirements, as well as compliance with Chinese laws and regulations relating to local manufacturing and global distribution of medical devices, drugs, food and cosmetic.

She has worked with multinational medical device and pharmaceutical companies to spot regulatory risks, prevent problems from happening, and resolve them in a practical manner. She has also worked with foreign universities to develop cooperative research programs in China. She has helped health care companies with the establishment of jointly-operated hospitals in China. Jessie also advises extensively on privacy, data protection, encryption, commercial franchising, and direct selling practice – the areas that are rapidly changing and highly regulated in China.

Representative experience

Advising a global jeweller and luxury goods retailer in relation to personal data protection, transfer and collection.



Phone

Email

jessie.xie@hoganlovells.com

Practices

Food Law

Health

Marketing and Advertising

Medical Device and Technology
Regulatory

Pharmaceuticals and Biotechnology
Regulatory

Privacy and Cybersecurity

Industries

Life Sciences and Health Care

Areas of focus

Consumer Product Safety
Regulation

Medical Foods and Dietary
Supplements

Food Advertising and Regulation

Advising a leading international company on its coffee brand franchise in China.

Advising a multinational pharmaceutical company in relation to the management and transfer of employee and patients data, develop the internal privacy policies.

Advising a U.S. based international company on its equity investment in a health care group.

Advising a U.S. medical device company on various matters including clinical trial, product recall, device refurbishment, product labels, product registrations, etc.

Advising a U.S. research institution on its collaborative project with Chinese parties on establishment of a cancer tissue repository in China.

Advising a U.S. university on hosting a medical facility on the campus.

Advising several international companies in relation to privacy policy and term of use agreements.

Advising various clients on regulations for advertisement and promotion of pharmaceutical and medical devices in China.

Advising various international companies on use and import of foreign encryption products.

Representing a German pharmaceutical company on restructuring its China entity which distributes drug products from an EJV into a CJV, and preparing relevant contracts.

Representing a leading U.S. based hospital group in negotiations to establish a jointly-operated hospital in China.

Awards and rankings

- Top 15 Rising star, *ALB China*, 2019

Latest thinking and events

- News
 - China update: Human Genetic Resources

Food Recalls

Food Legislation and Regulatory Policy Development

Product Development and Approval

Advertising and Promotion Compliance

Postmarket Compliance and Enforcement Actions

Premarket Review

Clinical Trials

Health Privacy and Cybersecurity

Workplace Privacy

Hospitals and Health Care Providers

Medical Devices

Pharmaceuticals and Biotechnology

Cell, Tissue, and Gene Therapies

Sports

Education and admissions

Education

LL.M., University of Aberdeen, 2006

LL.B., Guizhou University, 2004

Bar admissions and qualifications

People's Republic of China

Administration Rules support HGR Implementing Rules

- Hogan Lovells Events
 - Zurich: Life Sciences and Health Care Horizons 2024
- Insights and Analysis
 - Key considerations for life sciences demerger deals in China
- Insights and Analysis
 - Recent regulatory updates in China's Life Science Sector to start the year 2024
- News
 - JPM2024: Impact of China's HGR Rules on clinical trials and scientific studies involving China sites
- Insights and Analysis
 - Highlights on China's Long-awaited Implementing Rules on Human Genetic Resources Administration Rules